Anyone tune in this morning. Not a bad update from Glenn who highlighted a few solid pieces of info. Sounds like we will be getting updates in “coming weeks/months” about other cancers the company have in the pipeline for developing diagnostic technologies.
Other points of interest, again Glenn highlighted that FIT only detects blood in stool whereas ColoSTAT is for detection of the actual cancer and is 33% more accurate than FIT. The blood test can easily be included with other blood tests like cholesterol, liver etc. and reduces the need and expense for colonoscopy that FIT requires after detection of blood.
Sounds like CE Mark is on track
Projecting revenue 2022 $$$ - very large market - lower age testing given the cancer is a significant problem in the 25-30 age bracket. IMO potentially lowering testing to this age bracket given most amount of deaths occur in this bracket.
Sounds like the team at RHY very hard working and pumped about the test commercialisation.
This all may have been reflected in this arvos late SP run.
GLTAH.
Ann: AGM Presentation, page-2
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
